Asymptomatic hyperuricemia, arterial hypertension, cardiovascular risk: separate puzzles or a single picture?
Abstract
From 21 to 23 October 2021 in St. Petersburg under the motto «New challenges, new achievements. Cardiology of 21 years of the 21st century» was held by the Russian National Congress of Cardiology. Within its framework, on October 22, with the support of the Egis company, a symposium «Asymptomatic hyperuricemia, arterial hypertension, cardiovascular risk: separate puzzles or a single picture?». The experts discussed whether asymptomatic hyperuricemia is so asymptomatic; with the development of what diseases it is most often associated; what level of uric acid should be considered the threshold value for the initiation of urate-lowering therapy and which drugs have shown the greatest efficiency in this regard, including in comorbid patients.
References
1. Murashko M. A. To participants of the Russian National Congress of Cardiology. https://scardio.ru/content/activities/2021/Congress/ministr_letter.pdf.
2. Chazova I. Ye., Zhernakova Yu. V. ot imeni ekspertov. Clinical guidelines. Diagnostics and treatment of arterial hypertension. // Sistemnyye gipertenzii 2019; 16 (1): 6-31. DOI: 10.26442/2075082X.2019.1.190179.
3. Chazova Ye. I., Zhernakova Yu. V., Kislyak O. A., Nedogoda S. V. i soavt. Consensus on the management of patients with hyperuricemia and high cardiovascular risk. // Sistemnyye gipertenzii. 2019; 16 (4): 8-21. https://cyberleninka.ru/article/n/konsensus-po-vedeniyu-patsientov-s-giperurikemiey-i-vysokim-serdechno-sosudistym-riskom/viewer.
4. Yang W.X., Ma Y., Hou Y.I., 4, Wang Y.B., You C.G. Clin. Lab. 2019; 65 (8): 10, 7754/ Clin. Lab.2019, 190338.
5. Chen-Xu M., Yokose C., Rai S. K., Pillinger M.H. and Choi H. K., 2019; Arthritis Rheumatol., 71: 991-999.
6. Международная классификация болезней 10 (mkb-10.com). МКБ (Е79.0): https://mkb-10.com/index.php?pid=3314
7. Tin A. et al. Nat. Genet.51, 1459-1474 (2019).
8. Nakatochi et al. Commun. Biol. 2, 115 (2019).
9. Reginato A.M., Mount D. B., Yang I., Choi H. K. Nat. Rev. Rheumatol.2012; 8 (10): 610-621.
10. Desideri G. et al. Eur. Rev. Med. Pharmacol. Sci. 2014; 18: 1295-1306.
11. Hongsha Wang, Haifeng Zhang, Lin Sun, Weieing Gup. Am. J. Transl. Res. 2018; 10 (9): 2749-2763.
12. Yu W., Cheng J. D. Uric Acid and Cardiovascular Disease; an Update from Molecular Mechanism to Clinical Perspective / Front. Pharmacol 2020; 11: 582-680.
13. Yu J., Sun H., Zhu J. et al. Diabetes Metab. Syndr. Obes. 2021; 14: 1367-1374.
14. Fan S., Zhang P., Wang A. Y. et al. BMC Nephrol. 2019; 20 (1): 95.
15. Brucato A., Cianci F., Carnovale C. Management of hyperuricemia in asymptomatic patients: a critical appraisal // Eur. J. Intern. Med. 2020; 74: 8-17.
16. Awsan N., Ang D., Ogston S. et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. // The Lancet 2010; June 08, Open Access Published https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60391-1/fulltext
17. Richette P., Doherty M., Pascual E. et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout // Ann. Rheum. Dis. 2020; 1 (79): 31-38.
18. Nedogoda S. V., Barykina I. N., Salasyuk A. S., Smirnova V. O., Popova Ye. A. Prediabetes: Main Causes, Symptoms, Prevention and Treatment // Lekarstvennyy vestnik. 2018; 12 (2): 3-13.
19. Maloberti A ., Bombelli M., Facchetti R. et al. Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the Uric acid Right for heArt Health study // J. Hypertension. 2021; 2 (39): 156-163.
20. Verdecchia P., Schillaci G. et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension // Hypertension. 2000; 36 (6): 1072-1078. DOI: 10.1161/01.hyp.36.6.1072.
21. Pillinger M. H., Rosenthal P. et al. Hyperuricemia and gout: new insights into pathogenesis and treatment // Bull NYU Hosp Jt Dis. 2007; 65 (3): 215-221.
22. Alderman M. H., Cohen H., Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment // J. Hypertens. 1998; 16: 761-769.
23. Bengtsson C., Lapidus L., Stendahl C., Waldenstrom J. Hyperuricemia and risk of cardiovascular disease and overall death. A 12-year follow up of participants in the population study of women in Gothenburg, Sweden // Acta med. Scand. 1988; 224: 549-555.
24. Breckenridge A. Hypertension and hyperuricemia // Lancet. 1966; 1: 15-18.
25. Franse L. V. et al. Hypertension. 2000; 18: 1149-1154.
26. Cullerton B. F. et al. // Ann. Intern. Med. 1999; 31: 7-13.
27. Waring W. S., Webb D. J., Maxwell S. R. J. Effect of local hyperuricaemia on endothelial function in the human forearm vascular bed // Br J Clin Pharmacol. 2000; 49: 511.
28. Britten M. B., Elsner M., Walter D. H., Schachinger V. Elevated uric acid levels in hypercholesterolaemia are associated with coronary endothelial dysfunction (Abstr) // Circulation 1999; 100 (Suppl I): 6 (abstract no. 31).
29. Bagnati M., Perugini C., Cau C., Bordone R., Albano E., Bellomo G. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid // Biochem J. 1999; 340 (Pt 1): 143-152.
30. Boogaerts M. A., Hammerschmidt D. E., Roelant C., Verwilghen R. L., Jacob H. S. Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial injury // Thromb Haemost. 1983; 50: 576-580.
31. Duff G. W., Atkins E., Malawista S. E. The fever of gout: urate crystals activate endogenous pyrogen production from human and rabbit mononuclear phagocytes // Trans Assoc Am Physicians 1983; 96: 234-245.
32. Hutton C. W., Collins A. J., Chambers R. E., Whicher J., Dieppe P. A. Systemic response to local urate crystal induced inflammation in man: a possible model to study the acute phase response // Ann Rheum Dis. 1985; 44: 533-536.
33. Leyva F., Anker S. D., Godsland I. F. et al. Uric acid in chronic heart failure: a marker of chronic inflammation // Eur Heart J. 1998; 19: 1814-1822.
34. Patetsios P., Rodino W., Wisselink W., Bryan D., Kirwin J. D., Panetta T. F. Identification of uric acid in aortic aneurysms and atherosclerotic artery // Ann NY Acad Sci. 1996; 800: 243-245.
35. Butler R., Morris A. D., Belch J. J., Hill A., Struthers A. D. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension // Hypertension. 2000; 35: 746-751.
36. Cardillo C., Kilcoyne C. M., Cannon R. O., III, Quyyumi A. A., Panza J. A. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients // Hypertension. 1997; 30: 57-63.
37. Farquharson C., Butler R. A., Hill A., Belch J. J. F., Struthers A. D. Allopurinol improves endothelial dysfunction in chronic heart failure // J Am Coll Cardiol 1999; 33 (Suppl A): 216A.
38. Cardiology Journal // 2018; 5 (25):, 545–564. DOI: 10.5603/CJ.2018.011689.
Review
For citations:
Asymptomatic hyperuricemia, arterial hypertension, cardiovascular risk: separate puzzles or a single picture? Lechaschi Vrach. 2021;(12):85-89. (In Russ.)
Views:
195
JATS XML
Email this article 
